CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: Evidence for an allelic variant with altered catalytic activity

To determine the existence of mutant and variant CYP3A4 alleles in three racial groups and to assess functions of the variant alleles by complementary deoxyribonucleic acid (cDNA) expression.

[1]  M. Ingelman-Sundberg,et al.  Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region. , 1999, Biochemical and biophysical research communications.

[2]  M. Murray.  Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (review). , 1999, International journal of molecular medicine.

[3]  P. Nowell,et al.  Association of CYP3A4 genotype with treatment-related leukemia. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[4]  W. Sabbagh,et al.  SXR, a novel steroid and xenobiotic-sensing nuclear receptor. , 1998, Genes & development.

[5]  H. McLeod,et al.  Characterization of the human dihydropyrimidine dehydrogenase gene. , 1998, Genomics.

[6]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.

[7]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[8]  H. Yamazaki,et al.  Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. , 1997, Archives of biochemistry and biophysics.

[9]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[10]  F. Gonzalez,et al.  Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[11]  C. Ioannides.  Cytochromes P450 Metabolic and Toxicological Aspects , 1996 .

[12]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[13]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[14]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[15]  O Pelkonen,et al.  A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. , 1995, American journal of human genetics.

[16]  A. Vickers,et al.  Human liver cytochrome P4503A biotransformation of the cyclosporin derivative SDZ IMM 125. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[17]  P. Watkins,et al.  The erythromycin breath test predicts the clearance of midazolam , 1995, Clinical pharmacology and therapeutics.

[18]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[19]  S. Tagawa,et al.  Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. , 1993, European journal of biochemistry.

[20]  S. Scherer,et al.  Refined localization and yeast artificial chromosome (YAC) contig--mapping of genes and DNA segments in the 7q21-q32 region. , 1993, Human molecular genetics.

[21]  F. Gonzalez,et al.  Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6. , 1993, Pharmacogenetics.

[22]  H. Yamazaki,et al.  Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization , 1992, Japanese Journal of Human Genetics.

[23]  T. Aoyama,et al.  Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. , 1991, Archives of biochemistry and biophysics.

[24]  F. Gonzalez,et al.  Novel exogenous heme-dependent expression of mammalian cytochrome P450 using baculovirus. , 1989, Archives of biochemistry and biophysics.

[25]  M. Farrall,et al.  The gene CYP3 encoding P450pcn1 (nifedipine oxidase) is tightly linked to the gene COL1A2 encoding collagen type 1 alpha on 7q21-q22.1. , 1988, American journal of human genetics.

[26]  D. Waxman,et al.  Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. , 1988, Archives of biochemistry and biophysics.

[27]  O. Mcbride,et al.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. , 1988, DNA.

[28]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[29]  C. Walsh,et al.  Regioselectivity and stereoselectivity of androgen hydroxylations catalyzed by cytochrome P-450 isozymes purified from phenobarbital-induced rat liver. , 1983, The Journal of biological chemistry.

[30]  T. Omura,et al.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES. , 1964, The Journal of biological chemistry.

[31]  A. H. Phillips,et al.  Hepatic triphosphopyridine nucleotide-cytochrome c reductase: isolation, characterization, and kinetic studies. , 1962, The Journal of biological chemistry.

[32]  T. Rebbeck,et al.  More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. , 2000, Journal of the National Cancer Institute.

[33]  T. Rebbeck,et al.  Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. , 1998, Human mutation.

[34]  U. Meyer,et al.  Molecular mechanisms of genetic polymorphisms of drug metabolism. , 1997, Annual review of pharmacology and toxicology.

[35]  H. Yamazaki,et al.  Roles of cytochrome b5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. , 1996, Archives of biochemistry and biophysics.

[36]  K. Korzekwa,et al.  Cytochromes P450 expression systems. , 1995, Annual review of pharmacology and toxicology.

[37]  T. Shimada,et al.  Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[38]  D. Laurence,et al.  Clinical Pharmacology & Therapeutics , 1980, Palgrave Macmillan UK.